Navigation Links
Promising new nanotechnology for spinal cord injury
Date:4/2/2008

CHICAGO -- A spinal cord injury often leads to permanent paralysis and loss of sensation below the site of the injury because the damaged nerve fibers can't regenerate. The nerve fibers or axons have the capacity to grow again, but dont because they're blocked by scar tissue that develops around the injury.

Northwestern University researchers have shown that a new nano-engineered gel inhibits the formation of scar tissue at the injury site and enables the severed spinal cord fibers to regenerate and grow. The gel is injected as a liquid into the spinal cord and self -assembles into a scaffold that supports the new nerve fibers as they grow up and down the spinal cord, penetrating the site of the injury.

When the gel was injected into mice with a spinal cord injury, after six weeks the animals had a greatly enhanced ability to use their hind legs and walk.

The research is published today in the April 2 issue of the Journal of Neuroscience.

"We are very excited about this," said lead author John Kessler, M.D., Davee Professor of Stem Cell Biology at Northwestern University's Feinberg School of Medicine. "We can inject this without damaging the tissue. It has great potential for treating human beings."

Kessler stressed caution, however, in interpreting the results. "It's important to understand that something that works in mice will not necessarily work in human beings. At this point in time we have no information about whether this would work in human beings."

"There is no magic bullet or one single thing that solves the spinal cord injury, but this gives us a brand new technology to be able to think about treating this disorder," said Kessler, also the chair of the Davee Department of Neurology at the Feinberg School. "It could be used in combination with other technologies including stem cells, drugs or other kinds of interventions."

We designed our self-assembling nanostructures -- the buildin
'/>"/>

Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Promising new drug targets identified for Huntingtons disease
2. Unique whey protein is promising supplement for strict PKU diet
3. Cancer and arthritis therapy may be promising treatment for diabetes
4. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
5. New book defines promising young field of adult neurogenesis
6. UIC researchers find promising new targets for antibiotics
7. Strategy for nanotechnology-related environmental, health and safety research
8. Iridescence workshop promotes natures nanotechnology
9. FDLI, PEN co-sponsor major conference on nanotechnology
10. Using nanotechnology, UCLA researchers discover cancer cells feel much softer than normal cells
11. Nanotechnology and the media: The inside story
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... a complex cocktail of poisonous peptides that immobilize animal ... this cocktail damage only insects, which is why a ... a safe and ecologically sound pesticide. Prof. Michael ... has isolated the genetic sequences for important neurotoxins in ...
... the lichen Phylloblastia fortuita , new to the Iberian ... Phylloblastia dispersa , is also a new entry for ... outside the tropics. Foliicolous lichens, symbiosis between fungi ... and their presence in environments such as the Iberian Peninsula, ...
... COLUMBUS, Ohio Blocking the function of an enzyme in ... prevent nerve cells from dying after a stroke, new research ... found that the tocotrienol form of vitamin E, an alternative ... fatty acids that eventually kill neurons. The Ohio State ...
Cached Biology News:A deadly scorpion provides a safe pesticide 2A new species of lichen discovered in the Iberian Peninsula 2Study reveals how one form of natural vitamin E protects brain after stroke 2Study reveals how one form of natural vitamin E protects brain after stroke 3
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® announced the ... venture will bring the world’s most efficient gas dissolution technology to all of ... to both the industrial and municipal markets. With offices located in Sarasota, Sebring ...
(Date:7/27/2015)... July 27, 2015 Junto Health, a company ... information and develop new technology solutions, today announced the ... (SPG), a leader in health care policy consulting. Working ... in a collaborative innovation process while, at the same ... in public policy, health care finance and the delivery ...
(Date:7/26/2015)... (PRWEB) , ... July 26, 2015 , ... ... of its VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA ... Each VALIDATE® ANEMIA kit is prepared using the CLSI recommended “equal delta” method ...
(Date:7/24/2015)... ... ... VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency ... opportunities. , “We are very excited to be able to partner with VetStem Biopharma ... therapy is an established treatment for arthritic conditions in our pets and is also ...
Breaking Biology Technology:BlueInGreen Brings Water Treatment Technology to Florida 2Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3
... , RICHMOND, Va., July 31 Insmed Inc. ... that it will host a conference call on Thursday, August ... for the second quarter 2009. Insmed intends to issue ... on August 13(th). , , To participate ...
... TOKYO, July 31 R-Tech Ueno, Ltd. announced on July ... board of directors held on the day and determined the R&D ... to actively strengthen R&D in the ophthalmologic & dermatological fields that ... with external entities. , , 1. Development code ...
... , , , ... ANDS ) today announced finalization of the protocol for the ... ribavirin in hepatitis C patients. Allowance of the protocol has been ... dosing is expected to commence within the next several weeks. , ...
Cached Biology Technology:Insmed to Host Second Quarter 2009 Conference Call 2R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5
... Mouse monoclonal antibody raised ... Immunogen: ... 206 a.a) partial recombinant protein ... Accession Number: NM_005802 ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Agarose II (Low Melt)...
...
Biology Products: